The Federal Trade Commission is continuing its fight against alleged anti-competitive behavior in the pharmaceutical industry by pushing for federal legislation barring makers of brand-name prescription drugs from paying generic drug manufacturers to delay a generic drug release, which deprives consumers of affordable prescription drugs. Industry attorneys counter that proposed legislation banning such settlements would prolong patent court fights between generic and brand-name drug makers.
February 23, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
The Federal Trade Commission is continuing its fight against alleged anti-competitive behavior in the U.S. pharmaceutical industry by pushing for federal legislation that would bar makers of brand-name prescription drugs from paying generic drug manufacturers to delay a generic drug release.
The agency said the sharp rise of such anti-competitive settlements between the two types of drug makers deprives consumers of affordable prescription drugs.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
